arrow
E

Elena Tamborini

Department of Advanced Diagnostics
H指数:52
被引数:8,590

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center

液态活检用于评估和监测间变性甲状腺癌中的BRAF V600E:一项三级癌症中心的真实世界研究

2026-06-230
OAAI
Dissecting the Spectrum of Rare BRAF Mutations in Melanoma: A Nation-Wide Study by the Italian Melanoma Intergroup (IMI)

解析黑色素瘤中罕见BRAF突变的谱系:意大利黑色素瘤协作组(IMI)开展的一项全国性研究

2026-04-190
OAAI
Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study

分子检测和精准肿瘤学对晚期甲状腺癌患者的影响:一项OrienTHYring真实世界研究

2025-10-290
OAAI
Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancer

基因组不稳定性及CCNE1扩增作为分层高级别浆液性卵巢癌的新兴生物标志物

2025-08-070
OA
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial
2024-09-010
PRE
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial
2024-02-094
OAAI
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2

二甲双胍联合兰瑞肽治疗晚期胃肠道或肺神经内分泌肿瘤的安全性和抗肿瘤活性: Ib期试验MetNET2

2023-12-140
OAAI
Prognostic Factors Across Poorly Differentiated Neuroendocrine Neoplasms: a Pooled Analysis

低分化神经内分泌肿瘤的预后因素: 一项汇总分析

2022-11-237
PRE
Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles
2022-11-019
PRE
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study
2022-07-097
PRE
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers
2022-06-135
OA
Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
2022-04-083
OAAI
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients

PARERE试验的基本原理和研究设计: 在RAS和BRAF野生型化疗难治性转移性结直肠癌患者中,帕尼单抗再治疗后瑞戈非尼与反向序列的随机II期研究

2021-12-0116
PRE